A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy
Tekijät: Nieminen T, Knuuti J, Hamelahti P, Kahonen M, Laaksonen R, Janatuinen T, Vesalainen R, Nuutila P, Jokela H, Lehtimaki T
Kustantaja: ELSEVIER SCIENCE INC
Julkaisuvuosi: 2007
Journal: Vascular Pharmacology
Tietokannassa oleva lehden nimi: VASCULAR PHARMACOLOGY
Lehden akronyymi: VASC PHARMACOL
Vuosikerta: 47
Numero: 2-3
Aloitussivu: 113
Lopetussivu: 117
Sivujen määrä: 5
ISSN: 1537-1891
DOI: https://doi.org/10.1016/j.vph.2007.05.001
Tiivistelmä
High plasma homocysteine (Hey) has been linked to impaired endothelial function. We investigated whether treatment with pravastatin affects the Hey levels. Moreover, we studied whether the methylenetetrahydro to late reductase (MTHFR) C677T polymorphism affects coronary vasomotion at baseline and during the treatment with pravastatin. Fifty-one healthy, mildly hypercholesterolemic men (mean age 35 4 years) attended this randomised, double-blind, placebo-controlled study. The volunteers were randomised into groups with 6-month treatment with pravastatin (40 mg/day, n = 25) or placebo (n = 26). Coronary blood flow measurements with positron emission tomography at rest and during adenosine infusion as well as biochemical analyses were done at baseline and at the end of the treatment period. The Hey concentration decreased significantly during the pravastatin therapy (-0.81 +/- 1.46 mu mol/l, p = 0.01), but not during placebo (0.02 +/- 2.39 mu mol/l, p = 0.97). The MTHFR polymorphism did not affect the Hey concentration or coronary flow indices. Neither did the MTHFR polymorphism modulate the effects of pravastatin on coronary vasomotion. In conclusion, a 6-month therapy with pravastatin decreases Hey concentration in Finnish healthy young men. The MTHFR genotype is neither a determinant of baseline coronary flow indices nor does it modulate the effect of pravastatin on coronary reactivity. (C) 2007 Elsevier Inc. All rights reserved.
High plasma homocysteine (Hey) has been linked to impaired endothelial function. We investigated whether treatment with pravastatin affects the Hey levels. Moreover, we studied whether the methylenetetrahydro to late reductase (MTHFR) C677T polymorphism affects coronary vasomotion at baseline and during the treatment with pravastatin. Fifty-one healthy, mildly hypercholesterolemic men (mean age 35 4 years) attended this randomised, double-blind, placebo-controlled study. The volunteers were randomised into groups with 6-month treatment with pravastatin (40 mg/day, n = 25) or placebo (n = 26). Coronary blood flow measurements with positron emission tomography at rest and during adenosine infusion as well as biochemical analyses were done at baseline and at the end of the treatment period. The Hey concentration decreased significantly during the pravastatin therapy (-0.81 +/- 1.46 mu mol/l, p = 0.01), but not during placebo (0.02 +/- 2.39 mu mol/l, p = 0.97). The MTHFR polymorphism did not affect the Hey concentration or coronary flow indices. Neither did the MTHFR polymorphism modulate the effects of pravastatin on coronary vasomotion. In conclusion, a 6-month therapy with pravastatin decreases Hey concentration in Finnish healthy young men. The MTHFR genotype is neither a determinant of baseline coronary flow indices nor does it modulate the effect of pravastatin on coronary reactivity. (C) 2007 Elsevier Inc. All rights reserved.
Turun yliopiston Tutkimustietojärjestelmän portaali